Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca’s Tagrisso shows benefits in new lung cancer study

AstraZeneca’s Tagrisso shows benefits in new lung cancer study

21st November 2017

AstraZeneca has announced new clinical data showing the effectiveness of Tagrisso in the treatment of certain forms of lung cancer.

Results from the phase III FLAURA trial have shown the potential Tagrisso offers as a first-line therapy for patients with locally advanced or metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC).

Study participants with central nervous system (CNS) metastases at baseline experienced a higher objective response rate with their brain metastasis, suggesting a lower risk of CNS progression when treated with this drug than with current standard-of-care therapies.

CNS metastases are a common complication of NSCLC and can be extremely difficult to treat, as existing oral therapies are often unable to effectively cross the blood-brain barrier. As such, Tagrisso could deliver improved clinical outcomes in an area of great unmet medical need.

Sean Bohen, executive vice-president of global medicines development and chief medical officer at AstraZeneca, said: "Osimertinib represents the next generation of targeted therapies in EGFR mutation-positive NSCLC, and its CNS activity has been demonstrated in the AURA3, BLOOM and FLAURA trials."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.